Novel hydroxamic acid derivative induces apoptosis and constrains autophagy in leukemic cells

Fischer, Marten A.; Mustafa, Al-Hassan M.; Hausmann, Kristin; Ashry, Ramy; Kansy, Anita G.; Liebl, Magdalena C.; Brachetti, Christina; Piée-Staffa, Andrea; Zessin, Matthes; Ibrahim, Hany S.; Hofmann, Thomas G.; Schutkowski, Mike; Sippl, Wolfgang; Krämer, Oliver H.

doi:10.1016/j.jare.2023.07.005

Cited by 1 publication

(2 citation statements)

References 74 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Flow cytometry was performed as recently noted by us [9][10][11]. Annexin-V (indicator of early apoptosis; #130-093-060) was from Miltenyi Biotec, Bergisch Gladbach, Germany, and propidium iodide (PI; late apoptosis indicator) was from Sigma-Aldrich.…”

Section: Flow Cytometrymentioning

confidence: 99%

“…Details on immunoblotting were summarized by us [9][10][11]. The following antibodies were used: ATR (2790S), CHK1 (2360), cleaved caspase-3 (9661), CRBN (71810), PARP1 (9542) and p-CHK1 (S345) from Cell Signaling, Leiden, Netherlands; ATM (ab32420), DNA-PKcs (ab32566) and p-ATM (T1981) (ab81292) from Abcam, Cambridge, UK; GSPT1 (sc-515 615), HSP90 (sc-13 119) and vinculin (sc-73 614) from Santa Cruz, Heidelberg, Germany; p-ATR (T1989) (GTX128145) from GeneTex, Irvine, MA, USA; ɣH2AX (S139) (MAB3802) from Millipore, Schwalbach, Germany.…”

Section: Immunoblotting and Immunofluorescencementioning

confidence: 99%

See 1 more Smart Citation

Pharmacological degradation of ATR induces antiproliferative DNA replication stress in leukemic cells

Kansy,

Ashry,

Mustafa

et al. 2024

Molecular Oncology

View full text Add to dashboard Cite

Mammalian cells replicate ~ 3 × 109 base pairs per cell cycle. One of the key molecules that slows down the cell cycle and prevents excessive DNA damage upon DNA replication stress is the checkpoint kinase ataxia‐telangiectasia‐and‐RAD3‐related (ATR). Proteolysis‐targeting‐chimeras (PROTACs) are an innovative pharmacological invention to molecularly dissect, biologically understand, and therapeutically assess catalytic and non‐catalytic functions of enzymes. This work defines the first‐in‐class ATR PROTAC, Abd110/Ramotac‐1. It is derived from the ATR inhibitor VE‐821 and recruits the E3 ubiquitin‐ligase component cereblon to ATR. Abd110 eliminates ATR rapidly in human leukemic cells. This mechanism provokes DNA replication catastrophe and augments anti‐leukemic effects of the clinically used ribonucleotide reductase‐2 inhibitor hydroxyurea. Moreover, Abd110 is more effective than VE‐821 against human primary leukemic cells but spares normal primary immune cells. CRISPR‐Cas9 screens show that ATR is a dependency factor in 116 myeloid and lymphoid leukemia cells. Treatment of wild‐type but not of cereblon knockout cells with Abd110 stalls their proliferation which verifies that ATR elimination is the primary mechanism of Abd110. Altogether, our findings demonstrate specific anti‐leukemic effects of an ATR PROTAC.

show abstract

Section: Flow Cytometrymentioning

confidence: 99%

Section: Immunoblotting and Immunofluorescencementioning

confidence: 99%